ReviewSmall methods2026
Nanomedicine for Oral Delivery: Strategies to Overcome the Biological Barriers.
Review in Small methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Oral Poly(N-oxide) zwitterionic nanoplatform for Gambogenic Acid Enhances Mucosal penetration for potentiated anti-angiogenic therapy.International journal of pharmaceutics: X · 2026Article
- Formulation Characteristics of Solid-Dispersible Self-Emulsifying Drug Delivery Systems for Dual Drug Delivery.Pharmaceutics · 2026Article
- Oral Chitosan-Tripolyphosphate Nanoparticles Enhance the Metabolic Regulatory Effects of Snow Lotus Polysaccharide in Type 2 Diabetes.Pharmaceutics · 2026Article
- pH-Sensitive Dextrin-Based Nanosponges Crosslinked with Pyromellitic Dianhydride and Citric Acid: Swelling, Rheological Behavior, Mucoadhesion, and In Vitro Drug Release.Gels (Basel, Switzerland) · 2026Article
- Toward oral nanomaterial-based drug delivery systems for hepatocellular carcinoma therapy: evidence mapping, route-specific validation, and translational challenges.Frontiers in pharmacology · 2026Review
- Nanomedicine for Oral Delivery: Strategies to Overcome the Biological Barriers.Small methods · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Oral drug delivery is highly desirable for medical intervention due to its convenience, patient adherence, and non-invasiveness. Despite significant efforts, the successful oral delivery of therapeutics and prophylactics has been largely hindered by biological barriers that limit bioavailability. Researchers have since turned to nanoparticles as promising delivery vehicles that offer tunable properties to protect therapeutic payloads and enhance transport across these barriers. In addition to material optimization and delivery strategies, biomimetic designs-particularly those inspired by viruses-have significantly advanced the field, leveraging natural mechanisms to penetrate mucosal layers through size, charge, and enzymatic functions. This review examines the key physiological challenges limiting oral drug absorption, including the harsh gastric environment, the mucosal layer, and the polarized epithelial barrier. Recent preclinical advancements are then highlighted in nanoparticle engineering aimed at overcoming these barriers and improving bioavailability. Continued innovation in oral nanomedicine holds immense potential to revolutionize treatment paradigms, enhancing both therapeutic efficacy and patient outcomes worldwide.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.